Your session is about to expire
← Back to Search
Beta Blocker
Beta Blocker BABA Sequence for Heart Failure
Phase 4
Waitlist Available
Led By Parag Goyal, MD
Research Sponsored by Weill Medical College of Cornell University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline
Awards & highlights
Summary
This trial aims to see if patients with a specific type of heart failure can safely stop taking beta-blockers. Researchers will compare health outcomes during periods when patients are on the medication and when they are not. Beta-blockers have been extensively studied and shown to improve health outcomes in patients with heart failure.
Eligible Conditions
- Diastolic Heart Failure
- Heart Failure
- Cardiovascular Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Features of a Feasible and Pragmatic Protocol for Deprescribing N-of-1 Trials in Patients With Heart Failure With Preserved Ejection Fraction, as Measured by Qualitative Interview
Trial Design
2Treatment groups
Active Control
Group I: Beta Blocker BABA SequenceActive Control1 Intervention
This arm will follow a BABA sequence. "A" representing ON beta blockers and "B" representing OFF of beta blockers. Subjects in this arm will have their previously prescribed beta blocker dose reduced until they are completely off of beta blockers during Period 1. They will then crossover into Period 2, where uptitration will begin until they are back on their previously prescribed dose of beta blockers. After Period 2, the subjects have the option to decide if they want to be on or off their beta blocker and proceed with the Follow-Up Phase, or continue to Period 3 if they don't feel ready to make that decision to stay on or go off their beta blocker yet. During Period 3, we will again conduct a dose reduction, until the subject is off of beta blockers. Finally, during Period 4, we will up-titrate them back to their home dose of beta blockers.
Group II: Beta Blocker ABAB SequenceActive Control1 Intervention
This arm will follow an ABAB sequence. "A" representing ON beta blockers and "B" representing OFF beta blockers. Subjects in this arm will continue their home dose during the initial A period, they will then crossover into Period 2, where dose reduction will begin until they are off of beta blockers. After Period 2, the subjects have the option to decide if they want to be on or off their beta blocker and proceed with the Follow-Up Phase, or continue to Period 3 if they don't feel ready to make that decision to stay on or go off their beta blocker yet. During Period 3, they will restart beta-blockers, gradually up-titrating until reaching their home dose. Finally, during Period 4, we will again conduct a dose reduction until off of beta blockers.
Find a Location
Who is running the clinical trial?
Weill Medical College of Cornell UniversityLead Sponsor
1,078 Previous Clinical Trials
1,137,801 Total Patients Enrolled
11 Trials studying Heart Failure
42,783 Patients Enrolled for Heart Failure
National Institute on Aging (NIA)NIH
1,751 Previous Clinical Trials
28,123,806 Total Patients Enrolled
42 Trials studying Heart Failure
213,290 Patients Enrolled for Heart Failure
Parag Goyal, MDPrincipal InvestigatorWeill Medical College of Cornell University
1 Previous Clinical Trials
9 Total Patients Enrolled
1 Trials studying Heart Failure
9 Patients Enrolled for Heart Failure
Share this study with friends
Copy Link
Messenger